DEFA14A: Regeneron Pharmaceuticals Sets Date for 2024 Annual Meeting, Outlines Proposals for Shareholder Vote

Regeneron Pharmaceuticals has scheduled its annual shareholder meeting for June 14, 2024, and is soliciting votes on key proposals including the election of directors, ratification of auditors, and executive compensation.

Summary

• Regeneron Pharmaceuticals will hold its 2024 Annual Meeting on June 14, 2024.
• Shareholders are being asked to vote on several key proposals.
• These proposals include the election of five directors: N. Anthony Coles, Kathryn Guarini, Arthur F. Ryan, David P. Schenkein, and George L. Sing.
• Another proposal involves the ratification of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Shareholders will also vote on an advisory basis regarding executive compensation.
• A non-binding shareholder proposal requesting simple majority voting requirements will also be presented.
• Shareholders can vote online at www.ProxyVote.com or virtually during the meeting.
• The deadline to vote shares held directly is June 13, 2024, at 11:59 PM ET, and for shares held in a Plan, the deadline is June 11, 2024, at 11:59 PM ET.
• Shareholders can request a free paper or email copy of the proxy materials before May 31, 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting routine matters for shareholder vote. The sentiment is neutral to slightly positive as it reflects normal corporate governance processes.

Positives

• The document provides clear instructions for shareholders on how to vote.
• Shareholders have multiple options for accessing proxy materials and voting, including online and virtual participation.
• The proposals are clearly outlined, allowing shareholders to make informed decisions.

Industry Context

This is a standard annual meeting announcement, typical for publicly traded companies like Regeneron to engage with shareholders on key governance matters.

Comparison to Industry Standards

• The proposals listed are standard for a company of this size.
• The ability to vote online and request materials electronically is in line with industry best practices.
• The topics covered are similar to those addressed in proxy statements of comparable pharmaceutical companies such as Amgen, Gilead Sciences, and AbbVie.

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on, as they influence the company's governance and direction.
• Employees may be indirectly impacted by the decisions made regarding executive compensation and company strategy.

Key Dates

Keywords

Annual Meeting, Shareholder Vote, Proxy Statement, Regeneron, Directors, Executive Compensation, Auditor, PricewaterhouseCoopers